Option chain shows key data for root9B Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for root9B Holdings.

root9B Holdings (OTC:RTNB) Stock, Option Chain

root9B Holdings Inc is a provider of cybersecurity and business advisory services in regulatory risk mitigation. It designs and provides cybersecurity operations and solutions, risk mitigation services, compilation with complex regulations, and leverageable and integrated technology. The company provides its services through Cyber Solutions and Business Advisory Solutions segments. Cyber Solutions segment provides cyber operations assessments, analysis, and testing, to cyber training, forensics, exploitation, and strategic defense planning. It earns all its revenue from both of its segments.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AGHC

ANGI

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

ASDZF

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

BIG BLOCKCHAIN INTELGNCE by Big Blockchain Intelligence Group Inc.

BBKCF

BFALL

BSPK

BYZN

CCSB

CELLCUBE ENERGY STORAGE by Cellcube Energy Storage Sys Inc.

CECBF

CEFC

CHDGF

China TechFaith Wirelessmmunication Technology

CNTF

COFOL

CTIB

CYIG

DFMTF

DMNKF

DPLS

EOPT

ESTR

FLES

FRLI

FTPLF

FTXP

FUAPF

FUTL

GAXY

GBHPF

HQGE

HSKA

HTGM

INQD

INSYQ

IPNFF

IRIX

ISWH

IVITF

JINFF

MCIG

MRSN

MXROF

MYOV

NABIF

NOHO

NRBT

OPMZ

OXBDF

OZSC

PDLI

PDNLA

PHVAF

PTVL

QMC QUANTUM MINERALS CORP by QMC Quantum Minerals Corp.

QMCQF

REGEN BIOPHARMA INC PFD by Regen Biopharma, Inc.

RGBPP

RTNB

RTTR

SAMMF

SHGXY

SNAVF

SPLIF

STKXF

SYHBF

SZBI

TBEV

TRIB

TTNP

TUSK

TWOH

VIDA

VLRX

VRME

VVCIF

VYEY

WMLLF

FRFFF

UNJCF

GRDZF

DGTLF

BRTZF

SDXEF

SDPI

POROF

BFARF

SCYYF

NVLPF

GEEPF

GAYGF

MMIRF

GTARF

Stocks That Hit 52-Week Lows On Friday

Pre-Market Outlook

BGFV

CHKP

CIFS

CLLS

CRTO

CSTE

DNOW

EBIO

EMES

EVHC

FLKS

FORM

GRVY

ICON

IZEA

LBIX

MARA

NBEV

NTLA

NVMI

PYDS

QUMU

SGRY

SKLN

VBIV

VRML

WRLD

XNET

RMGN

45 Biggest Movers From Yesterday

AKER

AMPE

ARDX

ATRS

BLUE

CNET

DGLT

EGAN

ETRM

EXEL

FENC

FPRX

HIIQ

IMPV

LINU

MRDN

MTSI

NHTC

PETZ

RCON

SHLD

SNAK

TGTX

TNDM

TOPS

TRXC

VERI

35 Biggest Movers From Yesterday

ROOT9B HOLDINGS INC by root9B Holdings, Inc.

root9B Holdings Inc

Earnings

NIPG

NIP Group Reported H1 Revenue Of $39.34M Vs $38.56M YoY, EPS Loss Of $(1.04) Vs $(0.71) YoY

Macro Economic Events

Econ #s

Economics

Germany Ifo Business Climate Index For November 85.7 Vs. 86.1 Est.; 86.5 Prior

Germany Current Assessment For November 84.3 Vs. 85.4 Est.; 85.7 Prior

Germany Business Expectations For November 87.2 Vs. 87.0 Est.; 87.3 Prior

VivoPower International PLC (Nasdaq: "VVPR") (the "Company" or "VivoPower") is on track to file its Annual Report on Form 20-F for the fiscal year ending June 30, 2024, no later than November 29, 2024, in compliance with NASDAQ's filing requirements.
The delay in filing the Form 20-F has been primarily due to significant strategic changes, including the sale of the Aevitas critical power businesses, the business combination agreement involving Tembo e-LV B.V. and Cactus Acquisition Corp. 1 Ltd., and other previously announced updates. Additionally, the Company's management and auditors have been focussed on completing the audited accounts for Tembo e-LV B.V. ("Tembo"), a subsidiary of VivoPower, which are required to be included in the Registration Statement on Form F-4 to be filed in connection with Tembo's business combination with Cactus Acquisition Corp. 1 Ltd.
VivoPower anticipates filing the Form 20-F no later than November 29, 2024.
Upon filing the Form 20-F Annual Report, the Company will be able to proceed with its annual shareholder update call. Details of the call will be provided separately and will be available on the Company's website. VivoPower aims to release this information before Friday, December 6, 2024.

Government

Regulations

VVPR

VivoPower Targets November 29 for Form 20-F Filing Amid Strategic Changes and Tembo Business Updates, Prepares for Shareholder Update Call in December

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
An analysis of data from more than 9,000 propensity-matched patients in the STS/ACC TVT Registry1 demonstrated that those who received Edwards' newest generation SAPIEN 3 Ultra RESILIA valve experienced outstanding one-year outcomes that continuously surpassed recipients of the earlier generation SAPIEN 3 and SAPIEN 3 Ultra valves. Patients receiving the SAPIEN 3 Ultra RESILIA valve experienced extremely low mortality, low rates of reintervention, larger effective orifice areas, lower echo-derived gradients across all valve sizes and no paravalvular leak in 84.4% of cases.
"These strong, real-world data continue to demonstrate that patients treated with a SAPIEN valve experience excellent outcomes with rapid recovery and improved quality of life," said Larry Wood, Edwards' corporate vice president and group president, transcatheter aortic valve replacement and surgical structural heart. "These data add to the immense body of evidence with multiple years of follow up on the Edwards SAPIEN valve platform and more than 10 years of clinical experience with the RESILIA tissue."
Patients in the SAPIEN 3 Ultra RESILIA valve cohort, who had an average STS score of 3.6 and average age of 77, experienced meaningful quality of life benefits with a clinically significant average 31-point increase in KCCQ2 score and one-day length of hospital stay with 93% discharged to their homes.
"This is the first large-population study that showed the latest generation SAPIEN 3 Ultra RESILIA valve results in improved 1-year survival after TAVR versus prior generation valves, given it reduces mild or greater paravalvular leak," said Gilbert Tang, MD, MSc, MBA, Surgical and Academic Director of the Structural Heart Program for the Mount Sinai Health System and Professor and Vice-Chair of Innovation in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai. "This finding particularly affected low surgical risk patients, where the impact would matter more because of their longer life expectancies."
Dr. Tang is a consultant for Edwards Lifesciences. 1 The STS/ACC TVT Registry is a collaboration between the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC). 2 The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item survey that measures the impact of heart failure on a patient's quality of life, symptoms, and physical function.

Edwards Lifesciences' SAPIEN 3 Ultra RESILIA Valve Shows One-Year Outcomes: Data Presented at PCR London Valves

Highlights for the Quarter Ended September 30, 2024
<ul>
<li>Transaction volume was 7,046 units for the three months ended September 30, 2024, an increase of 25.7% from 5,605 units in the last quarter and an increase of 81.4% from 3,884 units in the same period last year.</li>
<li>Retail transaction volume was 6,005 units, an increase of 46.8% from 4,090&nbsp;units in the last quarter and an increase of 162.6% from 2,287 units in the same period last year.</li>
</ul>

UXIN

Uxin Limited Reported Q2 Transaction Volume Of 7,046 Units, Up 81.4% YoY, Retail Transaction Volume Of 6,005 Units, Up By 162.6% YoY

Business Outlook
For the three months ending December 31, 2024, the Company expects its retail transaction volume to be within the range of 7,800 units to 8,100 units. The Company estimates that its total revenues including retail vehicle sales revenue, wholesale vehicle sales revenue and other revenue to be within the range of RMB560 million to RMB580 million. The Company expects its Non-GAAP adjusted EBITDA to be positive. These forecasts reflect the Company's current and preliminary views on the market and operational conditions, which are subject to changes.

Guidance

Uxin Limited Expects Q3 Revenue Of RMB560M-RMB580M, Positive Adj EBITDA

Uxin Q2 Sales $70.85M Up From $48.80M YoY

<h3>Companies Reporting Before The Bell</h3>
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly loss at $0.10 per share on revenue of $4.12 million. 
• Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) is estimated to report earnings for its second quarter. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $227.49 million. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $68.00 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $1.58 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.16 per share on revenue of $5.95 million. 
<h3>Companies Reporting After The Bell</h3>
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $776.51 million. 
• Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $1.67 billion. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $706.77 million. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $707.30 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its third quarter. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly loss at $0.02 per share on revenue of $69.82 million. 
• Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $404.09 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $232.90 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $40.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.31 billion. 
• Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $1.16 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is likely to report quarterly earnings at $1.25 per share on revenue of $812.95 million. 
• Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) is expected to report quarterly earnings at $0.67 per share on revenue of $324.70 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $199.08 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $407.00 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $36.14 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $48.95 million. 
• Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is likely to report quarterly loss at $1.16 per share on revenue of $17.93 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

root9B Holdings

root9B Holdings (RTNB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga